# Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit

Review · Poul Flemming Høilund‐Carlsen, Abass A. Alavi, Jorge R. Barrio, Rudolph J. Castellani, Tommaso Costa, Karl Herrup, Kasper P. Kepp, Rachael L. Neve, George L. Perry, Mona-Elisabeth R. Revheim, Nikolaos K. R K Robakis, Stefano Luca Sensi, Bryce Vissel

- Archive id: doi:10.1016/j.arr.2024.102348
- Published: 2024-06-01
- Venue: Ageing Research Reviews
- DOI: https://doi.org/10.1016/j.arr.2024.102348
- PMID: 38830549
- Citations: 40
- Source URL: https://doi.org/10.1016/j.arr.2024.102348
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.